《美股業績》外科手術量反彈推高設備銷售 雅培次季利潤超出預期
雅培(ABT.US)公布,受惠外科手術量反彈推動醫療器械的需求,季度利潤超出預期,盈利跌31.8%至13.75億美元,調整後每股盈利為1.08美元,超出分析師預期的1.05美元。
期內,收入下跌11.4%至99.78億美元,其中醫療設備季度銷售額為43億美元,13億美元來自糖尿病設備Freestyle Libre;營養品銷售額為21億美元,雅培指去年密歇根工廠關閉後回收工廠生產的嬰兒奶粉後,於奶粉市場上失去的份額目前已恢復75%。
雅培維持全年每股盈利維持於4.3美元至4.5美元之間,全年按GAAP計算攤薄每股收益為3.02美元至3.22美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.